Navigation Links
Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress
Date:7/8/2010

BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia. These presentations follow Pfizer's recent announcement about the creation of a new research unit focused on rare diseases, including hemophilia.

"We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community," says Brenda Cooperstone, M.D., vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. "Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partnersincluding the World Federation of Hemophiliato help improve hemophilia care worldwide."

Early Research with Factor Xa and VIIa

Pfizer will present the results of a pre-clinical study in mice indicating that recombinant factor Xa therapy may provide a unique way to bypass deficiencies in the intrinsic pathway. Additional results from a preclinical study in mice suggest that a recombinant factor VIIa molecule with increased activity and duration of action may have the potential to improve inhibitor outcomes.

Additional Hemophilia Research from Pfizer at WFH

  • New model of antibody-induced hemophilia A for the assessment of bypass therapies
  • An electronic documentation system in Haemophilia provides otherwise unavailable feedback for continuous quality control first results from the Haemoassist system
  • A prospective registry of European hemophilia B patients receiving BeneFIX (nonacog alfa, recombinant human factor IX) for usual use
  • Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX
  • Safety and efficacy of B-domain-deleted recombinant FVIII final results of a 10 year pharmacovigilance study

Pfizer's Ongoing Commitment to the WFH and the Hemophilia Community

Pfizer will make a contribution to WFH at the meeting in support of the Twinning Program, which aims to increase the level of diagnosis and care for people with hemophilia by pairing emerging treatment centers and patient organizations with more established centers and organizations around the world. Wyeth, now part of Pfizer, has acted as the exclusive corporate sponsor of the world-renowned program since 2001, which currently has 32 Twinning partnerships worldwide. Historically, there have been 149 Twinnings. Pfizer will also host the annual reception for the Twinning Program.


'/>"/>

Contact: Gwen Fisher
Gwen.Fisher@Pfizer.com
484-865-5160
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Pfizer joins open-access medicinal chemistry public-private collaboration
2. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
3. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
4. Arizona Myeloma Network presents Special Award to TGen president
5. ItsHot.com Presents Aesthetic Diamond Jewelry and Diamond Watches at Wholesale Prices
6. Morehead Presents Webinar on “Managing the Paradox of Employee Alignment and Engagement”
7. RockWest Technology Group Presents Campus Contactless Card Technology at NACCU
8. NextAid Presents BIDS BUILD HOPE Online Auction to Benefit Projects on the Ground in Africa on World AIDS Orphans Day
9. Morehead Presents Webinar on “Creating a High-Performing RN Workforce”
10. AllianceDiamonds.com Presents: Facebook Diamond Giveaway 2010
11. Aderans Research Presents at SID (Society of Investigative Dermatology)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating ... Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices ...
(Date:1/20/2017)... ... ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's ... Tucker, son of Minister Delores Pinnock and a Jamaican native who lives in Kingston ... sitting up in bed, I felt a pounding headache. It was like a drum ...
(Date:1/19/2017)... ... ... With the cold weather here, many people will have to clear snow with snow blowers ... of snow, but they can be dangerous when used incorrectly. That’s why Amica Insurance ... proper use of snow blowers:, , When removing wet snow or ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Cosmetic Town, an ... surgery procedures in order to make it easier for their readers to get the ... body they impact as well as the techniques used on those particular areas. , ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: